267 related articles for article (PubMed ID: 35060000)
1. Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice.
Weber T; Schmitz R
Curr Oncol Rep; 2022 Jan; 24(1):13-21. PubMed ID: 35060000
[TBL] [Abstract][Full Text] [Related]
2. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS; Czuczman MS
Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
Morin RD; Arthur SE; Hodson DJ
Br J Haematol; 2022 Feb; 196(4):814-829. PubMed ID: 34467527
[TBL] [Abstract][Full Text] [Related]
4. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
6. Biological heterogeneity in diffuse large B-cell lymphoma.
Hilton LK; Scott DW; Morin RD
Semin Hematol; 2023 Nov; 60(5):267-276. PubMed ID: 38151380
[TBL] [Abstract][Full Text] [Related]
7. Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Naushad H; Bi C; Yu J; Bouska A; Rohr J; Chao W; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):73-88. PubMed ID: 26432520
[TBL] [Abstract][Full Text] [Related]
8. Genomic characterisation of diffuse large B-cell lymphoma.
Harrington F; Greenslade M; Talaulikar D; Corboy G
Pathology; 2021 Apr; 53(3):367-376. PubMed ID: 33642095
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.
Yenamandra AK; Smith RB; Senaratne TN; Kang SL; Fink JM; Corboy G; Hodge CA; Lu X; Mathew S; Crocker S; Fang M
Cancer Genet; 2022 Nov; 268-269():1-21. PubMed ID: 35970109
[TBL] [Abstract][Full Text] [Related]
10. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature.
Tirado CA; Chen W; García R; Kohlman KA; Rao N
J Hematol Oncol; 2012 Sep; 5():54. PubMed ID: 22967872
[TBL] [Abstract][Full Text] [Related]
13. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
14. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
Riedell PA; Smith SM
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
[TBL] [Abstract][Full Text] [Related]
17. Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.
Papageorgiou SG; Thomopoulos TP; Katagas I; Bouchla A; Pappa V
Ther Adv Hematol; 2021; 12():20406207211013987. PubMed ID: 34104369
[TBL] [Abstract][Full Text] [Related]
18. Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.
Patel SP; Harkins RA; Lee MJ; Flowers CR; Koff JL
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):234-243.e10. PubMed ID: 32063526
[TBL] [Abstract][Full Text] [Related]
19. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma.
Tagawa H; Suguro M; Tsuzuki S; Matsuo K; Karnan S; Ohshima K; Okamoto M; Morishima Y; Nakamura S; Seto M
Blood; 2005 Sep; 106(5):1770-7. PubMed ID: 15886317
[TBL] [Abstract][Full Text] [Related]
20. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
[Next] [New Search]